TLON Key Stats
- Talon Therapeutics, Inc. Reports First Quarter 2013 Financial Results GlobeNewswire May 15
- TALON THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report May 15
- TALON THERAPEUTICS, INC. Financials Apr 6
- Biotechs With Staggering Potential: Grant Zeng Apr 5
- Talon Therapeutics' CEO Discusses Q4 2012 Results - Earnings Call Transcript Seeking Alpha Apr 1
- Talon Therapeutics, Inc. Reports Fourth Quarter and Year End 2012 Financial Resu... Apr 1
- TALON THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial... Apr 1
- Talon Therapeutics to Host a Conference Call to Report 2012 Financial Results an... Mar 19
- TALON THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Of... Jan 25
- TALON THERAPEUTICS, INC. Files SEC form 8-K, Unregistered Sale of Equity Securit... Jan 11
TLON Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Talon Therapeutics is down 51.22% over the last year vs S&P 500 Total Return up 24.84%, Alnylam Pharmaceuticals up 156.7%, and Tekmira Pharmaceuticals Corporation up 139.9%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Pro Ratings for TLON
Pro Strategies Featuring TLON
Did Talon Therapeutics make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.